Parallel Advisors, LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
Parallel Advisors, LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$6,602
+699.3%
320
+1042.9%
0.00%
Q2 2023$826
+15.7%
28
-9.7%
0.00%
Q1 2023$71431
+210.0%
0.00%
Q3 2022$0100.0%0.00%
Q2 2022$010
+400.0%
0.00%
Q1 2022$0
-100.0%
2
-95.7%
0.00%
Q4 2021$2,000
+100.0%
46
+76.9%
0.00%
Q3 2021$1,0000.0%26
+116.7%
0.00%
Q1 2021$1,0000.0%120.0%0.00%
Q4 2020$1,000120.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders